Create your account

Analyse episodes, create alerts, spot trends before they go mainstream

Already have an account? Sign in

Companies

Compass Pathways

Mentioned in 4 analyzed podcast episodes across 4 shows

Episode Mentions

Making Sense with Sam Harris

Making Sense with Sam Harris · May 29, 2026

#478 — The Psychedelic Mind

Conducting Phase 2B and Phase 3 trials for psilocybin therapy using traditional clinical approaches

Psychedelic therapy protocolsFDA drug approval processClinical trial design
View Analysis
CNBC's "Fast Money"

CNBC's "Fast Money" · Apr 24, 2026

Intel Posts Best Day Since 1987 and Counting Down to Big Tech Results 4/24/26

Psychedelic stock rallying on FDA fast-track approval for mental illness research

Semiconductor Supply Chain and CPU DemandAI Infrastructure Investment and CapEx CyclesFed Leadership Confirmation and Monetary Policy
View Analysis
Squawk Pod

Squawk Pod · Apr 22, 2026

Gone Tripping: United CEO Scott Kirby & Psychedelic Therapy 4/22/26

Psychedelics company developing clinical treatments; Christian Angemeyer is a seed investor

Airline Industry Consolidation and Merger RegulationJet Fuel Price Volatility and Airline Pricing StrategyPsychedelic-Assisted Therapy Clinical Efficacy
View Analysis
Motley Fool Money

Motley Fool Money · Apr 12, 2026

The Psychedelic Revolution

Publicly traded psychedelic biotech (CNPS) advancing phase 3 trials for COMP360 psilocybin treatment with recent 23% stock jump

Psychedelic-Assisted Therapy Clinical EfficacyTreatment-Resistant Depression Market OpportunityFDA Approval Pathways for Psychedelic Compounds
View Analysis